The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Directors and Officers
    • Marketing & Promotions
    • The Antibody Society’s Committees
      • Meetings Committee
      • AIRR Community Working Groups & Sub-Committees
    • Sponsors & Partners
  • Society meetings
    • Computational Antibody Discovery: State of the Art
      • Computational Antibody Discovery Symposium Participants
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Biopharmaceutical Informatics Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2024
      • 2022 Antibody Engineering & Therapeutics
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 10 – 12 June, 2025 | Congress Center, Basel Switzerland.
      • Scientific Advisors, Antibody Engineering & Therapeutics Europe
    • FOCIS Symposia
  • AIRR Community
    • AIRR Community News
    • AIRR Community Newsletter
    • AIRR Community Seminar Series
    • AIRR Community Meetings
      • Zooming into the Community III
      • AIRR Community Meeting VII – Learnings and Perspectives
      • AIRR Community Special Event 2023  – Zooming in to the Community II
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • On AIRR – An AIRR Community Podcast
    • AIRR Data Commons
    • AIRR-C Germline Database Resources
    • AIRR Community Publications
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-Committees
      • Communications Sub-Committee
      • Executive Sub-Committee
      • Inferred Allele Review Committee
      • Meetings Sub-Committee
      • Strategic Planning Sub-Committee
    • AIRR Community Webinar Series
    • AIRR Community Calendar
    • AIRR Community Resources
  • Members only
    • Login
    • Note to members
    • Member discount codes
    • 2025 Calendar of Events
    • James S. Huston Antibody Science Talent Award
      • 2024 James S. Huston Antibody Science Talent Award Recipient
      • 2023 James S. Huston Antibody Science Talent Award Recipient
      • 2022 James S. Huston Antibody Science Talent Award Recipient
      • 2021 James S. Huston Antibody Science Talent Award Recipient
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • Huston Award submission guidelines
    • Research Competitions
      • Research Competition Winners
    • Science Writing Competition
      • Science Writing Competition Winners
    • Imaging Competition
      • Imaging Calendar Competition winners
        • The Antibody Society 2025 Calendar
        • The Antibody Society 2024 Calendar
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings in 2025
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody News Podcast
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars in 2025
    • The Antibody Series Lectures
    • Antibody Discovery & Development
    • Adaptive Immune Receptor Repertoires
    • Antibodies to Watch
    • Commercializing Antibody Therapeutics
    • Antibody Validation
      • 4th International Antibody Validation Meeting, Sep 2023
    • Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics
You are here: Home / COVID-19 / Untangling Pandemics in a Data-Driven World. The Evolution of SARS-CoV-2

Untangling Pandemics in a Data-Driven World. The Evolution of SARS-CoV-2

March 4, 2022 by The Antibody Society

Antibody Engineering & Therapeutics, held in December 2021, offered many opportunities to hear exciting and informative presentations by experts in the field. We are pleased to present here a summary of a plenary lecture by Prof. Kristian Andersen (Scripps Research Institute), kindly written by Dr. Czeslaw Radziejewski.

 

Untangling Pandemics in a Data-Driven World. The Evolution of SARS-CoV-2.
Kristian Andersen, Professor of Immunology and Microbiology, Scripps Research Institute

Professor Andersen’s lab conducts genomic epidemiology of different viruses using miniaturized PCR testing and large-scale genomic sequencing. Previously, his lab studied Lassa, West Nile, Ebola, and Zika viruses, and now the lab is examining SARS-CoV-2. The goal of the research to understand the emergence of new viruses and their local transmission,[1] as well as the evolution and spread of these viruses. In order to understand connectedness of the sequences, samples of virus are taken from the infected populations, then viruses are sequenced and analyzed.

SARS-CoV-2 was first detected in December 2019 in people who frequented the Wuhan Huanan market in Guangdong province, China. Based on large-scale sequencing, it was possible to estimate that the epidemic started in November 2019. SARS-CoV-2 is remarkably similar to SARS-CoV-1 in terms of the receptor in humans (ACE2), the animal reservoir (bats), and the fact that both are associated with wet markets.[2] The number of introductions in humans is at present unknown and any intermediate hosts are still also unknown. For SARS-Cov-1 the intermediate hosts were civets and raccoon dogs. Curiously, both viruses were introduced into humans in the month of November, SARS-Cov-1 in 2002, SARS-Cov-2 in 2019. Since 2002, trade and farming of wild animals have decreased in China, so the risk of multiple spillover was reduced. A farm in Hubei was previously found to have animals infected with SARS-CoV-1. Viral sequences determined in animals were very similar to those found in humans infected with SARS-Cov-1. The same farm recently had civets infected with SARS-CoV-2.

Since 1965, nine different coronaviruses have emerged in human population. Coronaviruses are part of Sarbecoviruses, which are widespread in Southeast Asia. Horseshoe bats are also widespread in that region and they are a reservoir of Sarbecoviruses. SARS-CoV-2 spreads easily and, unlike a seasonal influenza, it can infect both upper and lower parts of the respiratory system as well as other organs. High infectivity of many variants of CoV-2 can be attributed to the presence of the receptor binding domain (RBD) and also the presence of a polybasic cleavage site that allows the spike protein to be processed into two subunits and facilitates fast and widespread infection. The SARS-CoV-2 RBD is similar to the RBD of other viruses that infect animals such as bats and pangolins. SARS CoV-2 shows a very high rate of evolution, which in the past two years has resulted in multiple variants.[3] New variants have rapidly displaced the old ones. Omicron, which presumably emerged as a result of immune escape, has an extremely mutated lineage. For example, it has 40 mutations in the spike protein compared to original virus, most of which appears on the outside RBD of the spike protein. The mutations may lead to further optimization of binding to AC2, but also potentially usage of a coreceptor is involved. The spread of omicron is much faster than other variants. This variant is cable of causing new infection and reinfection. Almost entire the human population is susceptible to omicron infection, and SARS-CoV-2 now appears to be endemic.

In summary, SARS-Cov-2 is a fast-evolving virus and several factors such as evolutionary rate, mutational supply, mutational tolerance will determine its further evolution. However, we now have tools to fight the pandemics, including vaccines, anti-viral drugs, rapid tests, masks and better understanding of the virus.

1. Zeller et al. Emergence of an Early SARS-CoV-2 Epidemic in the United States. Cell 184(19):4939-4952, 2021. DOI: 10.1016/j.cell.2021.07.030.

2. Holmes et al. The Origins of SARS-CoV-2: A Critical Review. Cell 184(19):4848-4856, 2021. DOI: 10.1016/j.cell.2021.08.017.

3. Washington et al. Emergence and Rapid Transmission of SARS-CoV-2 B.1.1.7 in the United States. Cell 184(10):2587-2594, 2021. DOI: 10.1016/j.cell.2021.03.052.

Filed Under: COVID-19, SARS-CoV-2 Tagged With: COVID-19, SARS-CoV-2

Share this post

  • LinkedIn

mabs

mabs

The Official Journal of The Antibody Society

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • Zooming into the Community III Starts Tomorrow! May 20, 2025
  • Exciting news – The AIRR Community is turning 10! 🎂 May 8, 2025
  • The Antibody Society (TAbS): Win a FREE Attendance Pass to AET Basel & Present A Poster: Call For Abstracts! March 26, 2025

Archives

Follow us online

  • Email
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals